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Introduction: Chimeric mice with humanized livers were recently established by transplanting human hepatocytes.
This mouse model that is repopulated with functional human hepatocytes could be a useful tool for investigating
human hepatic cell biology and drug metabolism and for other preclinical applications. Successfully transplanting
human hepatocytes into mice requires that recipient mice with liver failure do not reject these human cells and
provide a suitable microenvironment (supportive niche) to promote human donor cell expansion and
differentiation. To overcome the limitations of current mouse models, we used Alb-TRECK/SCID mice for in vivo
human immature hepatocyte differentiation and humanized liver generation.
Methods: 1.5 μg/kg diphtheria toxin was administrated into 8-week-old Alb-TRECK/SCID mice, and the degree of
liver damage was assessed by serum aspartate aminotransferase activity levels. Forty-eight hours later, mice livers
were sampled for histological analyses, and the human donor cells were then transplanted into mice livers on the
same day. Chimeric rate and survival rate after cell transplantation was evaluated. Expressions of human hepatic-related
genes were detected. A human albumin enzyme-linked immunosorbent assay was performed after 50 days of
transplantation. On day 60 after transplantation, drug metabolism was examined in mice.
Results: Both human primary fetal liver cells and hepatic stem cells were successfully repopulated in the livers of
Alb-TRECK/SCID mice that developed lethal fulminant hepatic failure after administering diphtheria toxin; the
repopulation rate in some mice was nearly 100%. Compared with human primary fetal liver cells, human hepatic
stem cell transplantation rescued Alb-TRECK/SCID mice with lethal fulminant hepatic failure, and human hepatic
stem cell-derived humanized livers secreted more human albumin into mouse sera and also functioned as a
“human liver” that could metabolize the drugs ketoprofen and debrisoquine.
Conclusion: Our model of a humanized liver in Alb-TRECK/SCID mice may provide for functional applications such
as drug metabolism, drug to drug interactions, and promote other in vivo and in vitro studies.* Correspondence: ywzheng@md.tsukuba.ac.jp; rtanigu@med.yokohama-cu.ac.jp
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Because biomedical research cannot be performed in
humans, investigators commonly use mice for pharma-
ceutical testing [1], although these models are not always
useful. Most medically used drugs are primarily metabo-
lized in the liver. However, the same drug can be metab-
olized into different metabolites in mouse and human
livers due to species differences. Thus, it is quite often
difficult to determine whether a potential drug poses any
risks during development for clinical applications [2,3].
To address this problem, “humanized” mouse livers were
developed by growing human liver tissues inside mice [4-6].
These models exhibited responses to drugs similar to those
of the human liver. Current mouse models used for hu-
manized liver generation are primarily uPA+/+ (uroplasmi-
nogen activator) mice [4,7], Fah−/− (fumarylacetoacetate
hydrolase) mice [6], and a recently reported TK-NOG
(thymidine kinase) mouse.
However, previous reports showed that transplanted hu-
man immature cells or stem cells were less competitive as
compared with human adult hepatocytes in Alb-uPAtg
(+/−)Rag2(−/−) mouse livers [8-10]. Moreover, Fah−/−
mice could only provide a growth advantage for differenti-
ated hepatocytes but not for immature liver progenitor
cells [11]. In our laboratory, we also failed to transplant
human hepatic stem cells (HpSCs) into TK-NOG mice.
Thus, no useful mouse model for the efficient engraftment
of human immature liver cells currently exists.
To overcome this problem, we report here on a novel
Alb-TRECK/SCID mouse model that could be efficiently
repopulated with human immature hepatocytes. This trans-
genic mouse expresses human heparin-binding epidermal
growth factor-like receptor (HB-EGF)-like receptors under
the control of a liver cell-specific albumin promoter. After
administering diphtheria toxin (DT), this model mouse de-
veloped fulminant hepatitis due to conditionally ablated he-
patocytes, which provided space for donor cell residency
and proliferation [12]. Previous studies successfully trans-
planted mouse hepatocytes into Alb-TRECK/SCID mice
[13,14], but there have been no reports of generating a hu-
manized liver using Alb-TRECK/SCID mice.
In this study, we generated humanized livers in Alb-
TRECK/SCID mice by transplanting human primary
fetal liver cells (FLCs) and HpSCs. This humanized liver
provided an in vivo environment for universal stem cell
differentiation and also an opportunity to predict the
patterns of human drug metabolism and drug-to-drug
interactions.
Methods
Acute liver injury mouse model
Alb-TRECK/SCID mice were provided by our collabora-
tors at the Tokyo Metropolitan Institute of Medical Sci-
ence. Homozygosity was confirmed by backcrossing for atleast three generations. Alb-TRECK/SCID mice were
housed at Yokohama City University. Animal experimen-
tal work was conducted in accordance with the Guidelines
for Proper Conduct of Animal Experiments (Science
Council of Japan), and all experimental procedures were
approved by the institutional review board of the Animal
Research Center, Yokohama City University School of
Medicine (No.075).
DT (Sigma, St Louis, MO, USA; D0564-1MG) was in-
traperitoneally administered (1.5 μg/kg) to 8-week-old
Alb-TRECK/SCID mice, and the degree of liver damage
was assessed by serum aspartate aminotransferase (AST)
activity levels.
Donor cell culture
Human primary FLCs of embryonic age between weeks
14 and 18 were obtained from Cell Systems (Kirkland,
WA, USA). This study was conducted with the approval
of the ethics committee of Yokohama City University
(Approval No. A100903011).
Human primary FLCs were cultured in Dulbecco’s
modified Eagle’s medium with Ham’s F-12 nutrient mix-
ture (1:1 mixture; Sigma, St. Louis, MO, USA) supple-
mented with 10% fetal bovine serum, human γ-insulin
(1.0 μg/mL; Wako, Tokyo, Japan), nicotinamide (10 mM;
Sigma), dexamethasone (100 nM; Sigma), and L-
glutamine (2 mM; Gibco, Carlsbad, CA, USA) in dishes
coated with type IV collagen (Becton Dickinson Lab-
ware). After the first 24 hours of culture, human recom-
binant hepatocyte growth factor (50 ng/mL; Sigma) and
epidermal growth factor (10 ng/mL; Sigma) were added.
For cell passaging, culture medium was removed, cells
were treated with 0.05% trypsin- ethylenediaminetetraace-
tic acid (Gibco) at room temperature for 5 minutes and
then gently detached from the dish. Suspended cells were
neutralized and washed with culture medium that con-
tained 10% fetal bovine serum. The viability of dissociated
cells was never <90% based on trypan blue exclusion.
Human HpSCs were isolated using a DakoCytomation
MoFlo high-speed cell sorter (Beckman Coulter, Pasadena,
CA, USA) with cell antigens that included CDCP1, CD90,
and CD66 for a CDCP1+CD90+CD66− population. Details
for cell isolation were previously described [15]. These
cells were cultured using the same procedures as for hu-
man primary FLCs.
Liver biochemistry tests
After DT injection, blood samples were obtained from a
mouse tail vein every 24 hour and centrifuged at 4,000 rpm
at 4°C for 20 minutes. Serum samples were assayed for
serum AST activity measured with a FUJIFILM Kit accord-
ing to the manufacturer’s instructions (FUJIFILM, Tokyo,
Japan). Serum ASTactivity levels of mice used for cell trans-
plantation was measured at 48 hours after DT injection.
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Prior to cell transplantation, serum AST activity levels
were checked, and mice with AST values between
12,000 and 16,000 IU/L were used as recipients. When
cultured human primary FLCs or HpSCs reached 90%
confluence, these cells were detached and adjusted to a
final concentration of 1 × 106 viable cells per 50 μL cul-
ture medium. Human primary FLCs or HpSCs (1 × 106)
were transplanted into the spleens of Alb-TRECK/SCID
mice. Mice in the sham group received 50 μL sterile
saline.
BrdU injection
At 46 hours after DT was injected into Alb-TRECK/
SCID mice, BrdU (50 mg/kg) was administered intraper-
itoneally to five mice in each group, and mice were
sacrificed 2 hours later. Liver sections were prepared,
fixed with 4% paraformaldehyde (PFA) and washed with
0.05% Tween 20 in phosphate-buffered saline (PBS). Sec-
tions were then treated with 2 N hydrochloric acid and
neutralized with 0.1 M sodium tetraborate (pH 8.5). The
sections were then stained with an anti-BrdU antibody (BD
Pharmingen, San Jose, CA, USA), and Alexa Fluor®488 goat
anti-mouse IgG1 (Invitrogen, Carlsbad, CA, USA) was used
as a secondary antibody for visualization. Nuclei were
stained with 4′,6-diamidino-2-phenylindole (DAPI), and
sections were mounted with Apathy’s Mounting Media
(Wako Pure Chemical Industries, Osaka, Japan).
Histology and immunocytochemistry
Liver tissues were fixed with 10% neutral formalin for
2 days and washed with PBS for 1 day. After dehydration
with ethanol and xylene, tissues were embedded in paraf-
fin and serial sections were prepared (4 μm thick). These
samples were stained with hematoxylin and eosin.
For double or triple immunohistochemical staining, liver
tissues were frozen in optimum cutting temperature com-
pound (Sakura, Tokyo, Japan), liver sections (5 um thick)
were prepared and fixed in acetone:methanol (1:1) for
30 minutes, and then blocked with 10% normal goat
serum for 60 minutes. Sections were then incubated with
primary antibodies (1:200), including mouse anti-human
albumin mAb (Sigma), mouse anti-human CK19 mAb
(Dako, Tokyo, Japan), guinea pig anti-human CK8/18
(Progen, Heidelberg, Germany), mouse anti-human nuclei
(Millipore, Billerica, MA, USA), and mouse anti-Ki67
(Dako) at 4°C overnight. Sections were washed with PBS
and then incubated with appropriate Alexa-488, -555,
or -647-conjugated secondary antibodies (1:500; Invitro-
gen) at room temperature for 60 minutes. Cells were
counterstained with DAPI and sections were mounted
with Apathy’s Mounting Media (Wako Pure Chemical In-
dustries). Images were acquired using a Zeiss AxioImager
and microscope (Carl Zeiss, Jena, Germany).Real-time PCR
Total RNAs from humanized liver tissue and human pri-
mary FLCs and HpSCs and human adult hepatocytes
were extracted using Isogen reagent (Nippon Gene, To-
yama, Japan). cDNA was synthesized with a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Foster, CA, USA). Quantitative PCR was performed ac-
cording to the manufacturer’s protocol using TaqMan
Gene Expression Assays (Applied Biosystems) and data
were analyzed with an ABI PRISM® 7900HT Sequence
Detection System (Applied Biosystems). Probes used were
ALB (Hs00609411_m1), AFP (Hs01040607_m1), CYP3A4
(Hs01546612_m1), CYP2C9 (Hs00426397_m1), CYP2C19
(Hs00426380_m1), and hACTB (4326315E). TaqMan
Gene Expression Assay IDs (Applied Biosystems) are
shown in parentheses after the gene names.
Microarray analysis
Total RNAs were extracted from human primary FLCs,
HpSCs, and Alb-TRECK/SCID mouse livers that received
cell transplants separately for three independent experi-
ments using an RNeasy Mini Kit (Qiagen, Venlo,
Netherlands). RNA samples were individually hybridized to
a pool of two commercial normal ovary RNA on a Whole
Human Genome Agilent 4 × 44 K v2 Oligonucleotide
Microarray (Agilent Technologies, Santa Clara, CA, USA),
according to the manufacturer’s instructions. For cross-
species comparisons of expression profiles, total expression
data at the gene level were cross-referenced to other spe-
cies using the HomoloGene IDs in the Mouse Genome
Informatics curated data set of human–mouse orthology
with Phenotype Annotations [16]. To generate a heat map,
we used a hierarchical clustering method with Euclidean
distances for complete linkage on GeneSpring11.5.1. to
analyze 83 and 38 selected gene expression profiles. The
raw data of the microarray analysis have been deposited in
the Gene Expression Omnibus database (GSE62933).
Albumin assay
Blood samples (20 μl) were collected periodically from
mouse tail veins and centrifuged at 4,000 rpm at 4°C for
20 minutes. Serum samples were assayed for human albu-
min using a human albumin enzyme-linked immunosorb-
ent assay (ELISA) quantitation kit (Bethyl Laboratories
Inc., Montgomery, TX, USA), according to the manufac-
turer’s instructions. After 6 minutes, reactions were
stopped by adding 2 M sulfuric acid, and absorbance was
read at 450 nm using a Multimode Detector DTX 880
(Beckman Coulter, Pasadena, CA, USA).
Drug metabolite detection
At about 7 to 8 weeks, mice without and with cell trans-
plantation were intravenously administrated ketoprofen
(15 mg/kg), and urine samples were collected from 0 to
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quine (DEB) metabolic testing, mice were administered
DEB (2 mg∕kg) by oral gavage, and then blood samples
were obtained from tail veins at 0, 0.5, 1, 2, 4, and
8 hours with heparin-Na added. Plasma was separated
from blood by centrifugation. Metabolites were quanti-
fied using an LC-20A Series liquid chromatography-
tandem mass spectrometer (Shimadzu, Kyoto, Japan)
with an Intersil ODS-3 column (GL Science Co., Tokyo,
Japan). The details were previously described [17].
Statistical analysis
Results for two groups were statistically compared using
the Mann–Whitney U-test and results for more than
two groups were compared by one-way analysis of vari-
ance and Bonferroni multiple comparisons tests. A log-
rank (Mantel–Cox) test and the Kaplan–Meier method
were used to assess post-transplantation survival. A P-
value of <0.05 was considered significant. Statistical ana-
lysis was performed using Graphpad Prism software
(San Diego, CA, USA).
Results
Diphtheria toxin induces lethal fulminant hepatic failure
in Alb-TRECK/SCID mice
Alb-TRECK/SCID mice hepatocytes harbor the gene for
the human DT receptor, HB-EGF, under the control of
an albumin promoter, and exhibit cytotoxic effects after
DT administration. To evaluate the effects of DT injec-
tion on liver injury, we injected DT doses of 0.5, 1, 1.5,
2, and 5 μg/kg into groups of 8-week-old Alb-TRECK/
SCID mice (five per group) and measured serum AST
activity levels every 24 hours up to 96 hours after ad-
ministration of DT.
Serum AST activity reached a peak at 48 hours after
DT injection and then returned toward basal levels by
96 hours (Figure 1A). This indicated that acute liver fail-
ure might have occurred and that the most severe liver
damage might have been induced 48 hours after the ad-
ministration of DT. All mice were dead within 48 hours
after receiving 2 and 5 μg/kg of DT, and three mice were
dead by 72 hours while two mice survived after adminis-
tration of 1.5 μg/kg DT. All mice survived after adminis-
tration of 0.5 and 1 μg/kg DT. Thus, we defined 1.5 μg/kg
DT for 48 hours as a “sub-lethal dose” that could induce
fulminant hepatic failure.
Next, we histologically assessed pathological changes
in the liver at 48 hours after administration of DT in 8-
week-old mice with different serum AST activities. This
showed that, as compared with normal mice which were
not administered DT, after administration of DT there
was a disorganized hepatic architecture showing a cor-
rection for congestion with the increased serum AST ac-
tivity, and hepatocytes also had multiple, deeply stainedacidophilic cytoplasmic inclusions along with dark nuclei
(most probably apoptotic hepatocytes), while other hepa-
tocytes appeared either preserved or exhibited a vacuo-
lated cytoplasm with dark nuclei, along with little or no
portal vein inflammation (Figure 1B and Additional file
1: Figure S1).
Furthermore, after DT injection, all of the mice with
AST values of <8,000 IU/L had survived, the survival
rate of mice with AST values between 8,000 and
12,000 IU/L declined to about 60%, and it further de-
clined to 25% when the AST values were between 12,000
and 16,000 IU/L. All of the mice with serum AST activ-
ity levels of >16,000 IU/L were dead within 48 hours
(Figure 1C). These results were in agreement with those
of a previous study that showed that Alb-TRECK/SCID
mice were an ideal lethal fulminant hepatic failure model
generated by only a single DT injection [12,14].
Mouse hepatocyte proliferation is induced in response to
fulminant hepatic liver failure
To assess in vivo hepatocyte proliferation after the ad-
ministration of DT, we performed an immunohisto-
chemical analysis using cell cycle markers for total cell
cycle activity (Ki-67) and S-phase progression (BrdU in-
corporation, Cyclin A) in the livers of both normal mice
and mice with fulminant hepatic liver failure. This
showed that there was a higher degree of Ki67-positive
expression (Figure 2A, lower panels) and BrdU incorpor-
ation (Figure 2B, lower panels) in livers at 48 hours after
the administration of DT. In contrast, no positive Ki67
(Figure 2A, upper panels) and only a few BrdU-positive
cells (Figure 2B, upper panels) were detected in normal
mouse livers. These results showed that mouse liver re-
generation was occurring after DT injection.
Alb-TRECK/SCID mice with lethal fulminant hepatic failure
are rescued by human hepatic stem cell transplantation
Human immature hepatocytes, including human pri-
mary FLCs and HpSCs, could be used for long-term
in vitro culture. Human HpSCs exhibited uniform cell
morphology, with more ALB and fewer CK19-positive
cells as compared with human primary FLCs (Additional
file 1: Figure S2). Eight-week-old mice received DT in-
jections (1.5 μg/kg) 2 days before cell transplantation
and were checked for serum AST activity. Mice with
AST activity levels between 12,000 and 16,000 IU/L were
used as recipients and were transplanted with 1 × 106
cells, either human primary FLCs or HpSCs as described
in the experimental protocol (Figure 3A).
More than 60% of human HpSCs transplanted mice
survived for more than 120 days, whereas all of the hu-
man primary FLCs transplanted mice were dead within
110 days (Figure 3B). However, human primary FLCs
rescued mice in terms of survival at 7 days after
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Figure 1 Alb-TRECK/SCID mice develop fulminant hepatic failure after diphtheria toxin injection. (A) Serum aspartate transaminase (AST)
activity levels over time after diphtheria toxin (DT) injection during the first 96 hours. DT doses of 0.5, 1, 1.5, 2, and 5 μg/kg were injected into
8 week-old Alb-TRECK/SCID mice, and serum AST activity was determined every 24 hours. Results are means ± standard error of the mean
(n = 5/group). (B) Macroscopic views (left panels) and histology (hematoxylin and eosin (H&E) staining, right three panels) of mouse livers without
and with administration of DT after 48 hours. DT dose: 1.5 μg/kg, serum AST activity of normal liver: 30 IU/L; serum AST activity of DT-treated liver:
12,000 IU/L. CV, central vein; PV, portal vein. Scale bars = 100 μm. (C) Kaplan–Meier survival curves of Alb-TRECK/SCID mice with different AST activities
within 3 days after DT injection (numbers of mice in each group are indicated in the figure). *P< 0.05, **P< 0.01, ***P< 0.001. NS, not significant.
Zhang et al. Stem Cell Research & Therapy  (2015) 6:49 Page 5 of 12transplantation, as >80% of the sham group mice with
saline transplantation were dead within 7 days. Also,
mice with human primary FLCs exhibited a pronounced
body weight loss within 3 days after cell transplantation,
whereas mice that received human HpSCs showed a
gradual body weight increase similar to that of the sham
group (Additional file 1: Figure S3).
Whole mouse livers at 6 weeks after cell transplantation
were grossly examined under a microscope (Figure 3C, left
panels) and by histological examination, which showed
that both human primary FLCs and HpSCs had recon-
stituted the liver structure by replacing original mouse
hepatocytes (Figure 3C, middle and right panels). Macro-
scopically, at 4 days after human HpSC transplantation,
we detected small human hepatic clusters that were uni-
formly distributed around the liver and had proliferated
into large clusters at 45 days (Additional file 1: Figure S4A).
Thus, these whole mouse livers that had been replaced withhuman hepatocytes were designated “humanized livers”
(Additional file 1: Figure S4B). These results showed
that mice with lethal fulminant hepatic failure that
underwent human primary FLC transplantation sur-
vived over a short term, whereas for long-term survival
transplanted human HpSCs might have been functional.
Both human primary FLC- and HpSC-derived human-
ized livers were healthy and exhibited liver structures
similar to normal mouse livers.
Proliferative human hepatic stem cells successfully
differentiate in humanized livers of Alb-TRECK/SCID mice
Prior to testing whether the transplanted human immature
hepatocytes in mice had the potential for differentiation
and be functional in vivo, we firstly confirmed human hepa-
tocytes existed in mouse livers by immunohistochemical
analysis at about 6 weeks after transplanting human pri-

































Figure 2 Extensive mouse hepatocyte proliferation after administration of diphtheria toxin. Immunofluorescent staining for cell
proliferation markers Ki67 (A) and BrdU (B) in liver tissues from 8-week-old Alb-TRECK/SCID mice without and with diphtheria toxin (DT)
treatment. DT-treated mouse liver with serum aspartate aminotransferase activity of 12,000 IU/L was sampled at 48 hours. At 2 hours before
sampling, BrdU (50 mg/kg) was administered intraperitoneally. Experiments were performed with five mice/group, and representative images are
shown. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Scale bars = 100 μm.
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ically positively co-stained with human nuclei and human
cytokeratin 8/18 (CK8/18) antibodies were donor cell-
derived human hepatocytes, while the original liver regions
in mice were negative for these markers.
To assess the degree of cell differentiation in vivo,
we immunohistochemically assessed for human albu-
min (ALB) and human cytokeratin 19 (CK19) expres-
sions. This showed that human primary FLC-derived
liver sections that were positively stained with human
CK8/18 were human ALB and CK19 negative (Fig-
ure 4A, right panels), whereas human HpSC-derived
human hepatocytes in mouse livers were well differen-
tiated and with upregulated human ALB expression.
Human ALB-positive hepatocytes that were CK19
negative resembled functional hepatocytes, while cells
that positively co-stained with human ALB and CK19
exhibited a bipotential capability with differentiationinto hepatocytes and cholangiocytes (Figure 4B, right
panels).
A large-scale scan method to analyze the entirety of
human HpSC-derived humanized liver lobes showed that
multiple round and colony-like clusters were distributed
around the liver lobes with clear human nuclei, and CK8/
18 and ALB expression (Additional file 1: Figure S5), indi-
cating that the colony-forming capability of human HpSCs
were maintained in humanized livers.
These results showed that, compared with human pri-
mary FLCs, human HpSCs had a high potential for differ-
entiation into functional hepatocytes in vivo in response
to the rescue of damaged mouse liver functions.
Characterization of human drug metabolism gene
expression in Alb-TRECK/SCID mouse with humanized livers
We also evaluated human drug metabolism-related gene
expression by quantitative PCR and microarray analysis













































































Figure 3 Transplanting human primary fetal liver cells and human hepatic stem cells into Alb-TRECK/SCID mice with fulminant hepatic
failure. (A) Experimental protocols. Forty-eight hours after the intraperitoneal injection of diphtheria toxin (DT), mouse serum was collected for
the aspartate aminotransferase (AST) assay, and mice livers (n = 5) were sampled for histological analyses. The human donor cells were then
transplanted into mice livers (n = 54/group) on the same day. A human albumin enzyme-linked immunosorbent assay was performed after 50 days
of transplantation (n = 6/group). On day 60 after transplantation, drug metabolism was examined in mice (n = 4 or more/group), and over 20 mice
per group were used for the survival tracing. Mice that survived for more than 120 days were sacrificed for liver tissue sampling. (B) Kaplan–Meier
survival curves of Alb-TRECK/SCID after transplantation with human primary fetal liver cells (FLCs) and human hepatic stem cells (HpSCs).
(Numbers of transplanted mice in each group are indicated in the figure.) *P < 0.05, **P < 0.01. (C) Macroscopic views (left panels) and histology
(hematoxylin and eosin (H&E) staining, right two panels) of humanized livers with human primary FLCs (upper panel) and human HpSCs (lower
panel) at 6 weeks after transplantation. CV, central vein; PV, portal vein; m, mouse liver region; h, human donor cell-derived human region.
Scale bars = 100 μm.
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derived humanized livers could be used for human drug
metabolism studies. At 8 weeks after transplantation, we
observed very high gene expression levels associated
with the human hepatic functional markers ALB, AFP,
and cytochrome P450, including CYP3A4, 2C9, and
2C19, which collectively metabolize over 80% of clinical
drugs (Figure 5A). Almost none of the probes on the hu-
man gene expression array had cross-hybridized with
murine mRNA.
To comprehensively assess for genes associated with
drug metabolizing enzymes, we performed microarray ana-
lysis for 83 previously reported human drug metabolism-
related genes (Figure 5B) and 38 mature hepatocyte-specific genes (Additional file 1: Figure S6A) whose ex-
pressions were robustly increased in humanized livers. We
chose the 83 genes because their expression increased
continuously during both murine and human liver devel-
opment [18], and the subset of 38 genes was used to iden-
tify differentiated hepatic characteristics [19]. Three
pairwise comparisons selectively displayed genes with a
twofold expression change (increase or decrease) in hu-
manized livers derived from human HpSCs, human
HpSCs and human adult hepatocytes, and showed that
humanized livers shared 1,049 genes with human adult
hepatocytes, which included liver-specific genes, ALB,
AFP and ABCC6, and genes for drug metabolizing en-




















































































































Figure 4 Characterization of human primary fetal liver cell- and human hepatic stem cell-derived human hepatocytes in Alb-TRECK/
SCID mice. (A) Immunohistochemistry to distinguish between human hepatocytes stained with anti-human CK8/18 (green) antigen and
anti-human nuclear antigen (aqua blue) in human primary fetal liver cell- (FLC; upper panels) and human hepatic stem cell- (HpSC; lower panels)
derived humanized livers at 6 weeks after transplantation. (B) Immunohistochemistry analyses for human albumin, human CK19, and human CK8/
18 expression in human primary FLC- (upper panels) and HpSC- (lower panels) derived livers at 6 weeks after transplantation. White dashed line:
mouse liver region distinguished from human liver region. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, blue). Scale bars
= 100 μm. m, mouse liver region; h, human donor cell-derived human region.
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phase I, 86 of 99 phase II, and 35 of 51 phase III genes
could be detected in humanized livers derived from hu-
man HpSCs, similar to that of human adult hepatocytes
(Additional file 1: Figure S6C and Additional file 3). These
results indicated that relevant functional human drug me-
tabolizing enzymes were expressed in humanized livers
derived from human HpSCs, which could be useful for
preclinical drug development.
Functional characterization of humanized livers in
Alb-TRECK/SCID mice
At about 8 weeks after transplantation, the level of liver
repopulation with human donor cells and human ALB
concentrations in mouse sera were determined. The
average liver repopulation rate for human primary FLC-
and HpSC-derived humanized livers were 76% and 71%,
respectively; no significant difference was observed. Sev-
eral humanized livers reached liver repopulation levels
of about 100%, which indicated that almost the entiremouse liver had been reconstituted with human hepato-
cytes (Figure 6A). Humanized livers derived from human
HpSCs resulted in more human ALB secretion than
those from human primary FLCs, and no human ALB
could be detected in mice after saline transplantation
(Figure 6B). The drug metabolism profiles based on gene
expression and human ALB secretion patterns suggested
the potential of humanized livers derived from human
HpSCs for early identification of major drug metabolites
in vivo.
We administered ketoprofen (KTP) [20] and DEB [21],
which are known to be metabolized differently by mice
and humans, into sham-treated mice and mice trans-
planted with human hepatocytes. KTP, a CYP2C9 sub-
strate, is primarily metabolized to KTP-glucuronide
(KTP-glu) by humans and metabolized to hydroxyl-KTP
in mice. DEB is a prototypical CYP2D6 substrate that is
converted to its 4OH metabolite (4OH DEB) by
CYP2D6. The fold-change of KTP-glu/M1 was signifi-
cantly greater in human HpSC-derived humanized livers
Figure 5 (See legend on next page.)
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Figure 5 Expressions of human hepatocyte-related genes in human primary fetal liver cell- and human hepatic stem cell-derived
humanized livers. (A) Results of quantitative PCR for the expression of functional hepatocyte markers, including hALB, hAFP, hCYP3A4, hCYP2C9,
and hCYP2C19, in samples taken before and about 8 weeks after human primary fetal liver cell (FLC) and human hepatic stem cell (HpSC)
transplantation. Results are mean ± standard error of the mean (n ≥ 4 mice/group). (B) Heat maps for 83 human-specific drug metabolism genes
and transcription factors, shown separately for independent experiments to analyze human primary FLCs and HpSCs before and at 8 weeks after cell
transplantation. Human adult hepatocytes were used as a positive control. AH, adult hepatocyte; ND, not detectable; Sham, mice transplanted with saline.
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and sham-treated mice (Figure 6C). For DEB, a higher
metabolic ratio of 4OH-DEB/DEB was detected in hu-
man HpSC-derived humanized livers (Figure 6D).
These results showed that human HpSC-derived hu-
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Discussion
Recent studies have shown that mouse livers could be
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used as a preclinical experimental model for drug metab-
olism testing [23] and drug discovery and development
[24], and they also provided an in vivo environment for
cell maturation and differentiation [25]. The major aim of
the present study was to generate a novel acute liver dis-
ease mouse model that provided for human immature
hepatocyte proliferation, maturation, and differentiation in
order to acquire drug metabolism activities.
It was clear that this novel Alb-TRECK/SCID mouse
model developed lethal fulminant hepatic failure using
one dose of DT, which provided a platform for studying
the basic biology of liver regeneration after injury and
liver disease development. As is known, even human im-
mature hepatocytes can proliferate extensively in vitro,
although they lose drug metabolism functions which
limits their preclinical applications [26]. After trans-
planting human immature hepatocytes, including human
primary FLCs and human HpSCs, into Alb-TRECK/
SCID mice with lethal fulminant hepatic failure, we
found histological and immunohistochemical evidence
that both human primary FLCs and HpSCs could ex-
pand and reconstitute the damaged mouse liver struc-
tures; the repopulation rate in some mice was nearly
100%.
However, as compared with human primary FLCs, hu-
man HpSC transplantation promoted mouse survival
and resulted in more human ALB secreted into mouse
sera. These cells also exhibited maturation and differen-
tiation in vivo with human drug metabolism activities,
which indicated that humanized livers in mice derived
from human HpSCs were similar to a mature, functional
“human organ” and have potential applications in drug
development. This further confirmed that Alb-TRECK/
SCID mice were an ideal model for humanized liver
generation.
Despite the prospects and advantages of Alb-TRECK/
SCID mice as an ideal model for human HpSC-derived
humanized liver generation, there was one unique disad-
vantage as well. We transplanted human adult hepato-
cyte into three Alb-TRECK/SCID mice with one DT
dose treatment and failed to get the humanized livers,
possibly because human adult hepatocytes lacked the
capability to proliferate. Additional DT doses cannot be
administered after human adult hepatocyte transplant-
ation. Since the DT receptor (HB-EGF) in Alb-TRECK/
SCID mice hepatocytes is under the control of the albu-
min promoter, additional DT treatment will destroy
transplanted human adult hepatocytes in the mouse
liver.
Thus, Alb-TRECK/SCID mice can sustain acute liver
injuries with only one DT dose injection and are easily
bred recipients for human immature hepatocyte trans-
plantation. They are an acceptable model for humanHpSC transplantation as they provide a beneficial envir-
onment that allows for the differentiation into mature
hepatocytes. These mice are certainly an interesting
model that has tremendous potential applications, not
only for ex vivo expansion of human hepatocytes, but
also to test candidate therapeutic drugs for liver toxicity
and metabolism as well as for drug screens.
Conclusions
Overall, we have shown that Alb-TRECK/SCID mice are
an ideal model for induced lethal fulminant hepatic fail-
ure that could be used to study hepatocyte regeneration
and liver disease development and facilitate in vivo hu-
man immature hepatocyte differentiation; it also has the
potential for human drug metabolism testing. After hu-
man immature hepatocytes, including human primary
FLCs and HpSCs, were transplanted into Alb-TRECK/
SCID mice administered DT, damaged mouse livers were
reconstituted with high liver repopulation rates. Further-
more, human HpSC transplantation-derived humanized
livers exhibited higher human liver functions, including
human ALB secretion and drug metabolism capabilities.
Thus, our model of humanized livers in Alb-TRECK/
SCID mice allows for the use of functional applications,
such as examinations of drug metabolism, drug–drug in-
teractions, and hepatic virus transfection, and the pro-
motion of human HpSC-related studies, such as in vivo
evaluation of stem cell differentiation and development
processes.
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